11/17/2020 | BK | Covis Finco restates $954 million credit agreement as AMAG buy closes
|
11/17/2020 | CVLM | AMAG 3¼% convertibles due 2022 are putable, amended as merger closes
|
10/5/2020 | CV | Market Commentary: Livent convertible notes in focus, expand in secondary; Cinemark tanks; AMAG trades down
|
10/1/2020 | CV | Market Commentary: AMAG convertibles skyrocket on buyout; j2 Global active; SolarEdge gains outright
|
10/1/2020 | CVLM | AMAG 3¼% convertible holders to have put right following merger
|
10/1/2020 | BK | Covis to acquire AMAG, $647 million debt obligations
|
10/1/2020 | CV | Market Commentary: Morning Commentary: AMAG convertibles skyrocket on buyout rumors; j2 Global active
|
8/12/2019 | CV | Market Commentary: Akamai, Workiva on tap; Insight Enterprises eyed; Snap active; Alteryx notes improve
|
3/20/2019 | CV | Market Commentary: Chegg on tap; GOL Linhas accelerates timing; Euronet dominates; Nio notes open up
|
3/20/2019 | CV | Market Commentary: Morning Commentary: Convertibles secondary space quiet; Euronet continues to dominate
|
3/8/2019 | CV | Market Commentary: Pluralsight convertible notes in focus; Aceto jumps; AMAG contracts; NIO down again
|
11/1/2018 | CV | Market Commentary: Wayfair convertibles eyed; Booking Holdings active; AMAG drops; Chesapeake in focus
|
9/27/2018 | BKCV | S&P lifts, then withdraws AMAG Pharma rating
|
9/6/2018 | HYLM | AMAG Pharmaceuticals redeems 7 7/8% notes via Cord Blood proceeds
|
6/18/2018 | BKCVHY | S&P puts AMAG on positive watch
|
6/15/2018 | HY | Market Commentary: PHI joins calendar, existing notes gain; MGM dominates; Ardent trades up; AMAG jumps
|
6/15/2018 | BKCVDDEMIGPV | Market Commentary: PHI joins calendar, existing notes gain; MGM dominates; Ardent trades up; AMAG jumps
|
6/15/2018 | CV | Market Commentary: TPG Specialty, Canopy convertibles price; Intelsat up 12 points on week; AMAG in focus
|
6/15/2018 | CV | Market Commentary: Morning Commentary: TPG Specialty, Canopy price; Intelsat up 12 points dollar neutral
|
6/15/2018 | HYLM | AMAG Pharmaceuticals to repay 7 7/8% notes with Cord Blood proceeds
|
4/12/2018 | CV | Market Commentary: Transocean convertibles in focus; primary quiet; biotech sector firm; Caesars active
|
2/27/2018 | BKBWHY | AMAG has ‘high degree’ of flexibility, de-levers by 20% during 2017
|
2/20/2018 | CV | Market Commentary: Q2 Holdings on tap; NXP Semiconductors active on buyout offer increase; AMAG tops par
|
2/15/2018 | HY | Market Commentary: Primary stays quiet, overall market firms; Bombardier up on Q4; funds plunge $6.3 billion
|
2/15/2018 | BKCVDDEMIGPV | Market Commentary: Primary stays quiet, overall market firms; Bombardier up on Q4; funds plunge $6.3 billion
|
2/15/2018 | CV | Market Commentary: AMAG convertibles in focus; Red Hat reaches new heights; Oil States drops below par
|
2/15/2018 | CV | Market Commentary: Morning Commentary: Inpixon prices convertible preferred offering; AMAG in focus
|
1/30/2018 | BKCVHY | S&P lowers AMAG, notes
|
11/3/2017 | CV | Market Commentary: Convertibles mixed; Intel pulls back but up for week; AMAG finds footing after tumble
|
11/3/2017 | CV | Market Commentary: Morning Commentary: Convertibles mixed; AMAG finds footing after tumble following lowered guidance
|
8/18/2017 | CV | Market Commentary: Jazz prices at discount, fades post-pricing; AMAG convertibles hold steady; DyCom sees action
|
8/18/2017 | CV | Market Commentary: Morning Commentary: Jazz prices at discount, fades post-pricing; AMAG convertibles hold steady
|
5/15/2017 | BK | AMAG Pharmaceuticals repays, terminates term loan via convertibles
|
5/12/2017 | BKCVHY | Moody’s raises AMAG notes to Ba3
|
5/8/2017 | BKCVHY | S&P affirms AMAG, lifts notes to BB-
|
5/5/2017 | CV | Market Commentary: AMAG deal comes upsized, cheap; HubSpot ‘aggressively priced’; Herbalife edges higher
|
5/5/2017 | CV | Market Commentary: Morning Commentary: AMAG Pharmaceuticals deal comes upsized, cheap; HubSpot prices rich
|
5/5/2017 | CV | New Issue: AMAG sells upsized $300 million five-year convertibles yield 3.25%, up 37.5%
|
5/4/2017 | CV | Market Commentary: Spirit Realty convertibles tumble on earnings miss; Lumentum trades higher on 3D hopes
|
5/3/2017 | CV | Market Commentary: AMAG, HubSpot add deals to calendar; Tesla drops ahead of earnings; Akamai trades off
|
5/3/2017 | CV | AMAG offers $250 million five-year convertible notes at 2.75%-3.25% yield, up 37.5%-42.5%
|
3/2/2017 | SP | New Issue: JPMorgan sells $1 million 9% yield notes on AMAG Pharmaceuticals
|
2/21/2017 | BKCVHY | Moody’s revises AMAG view to stable
|
1/9/2017 | CV | Market Commentary: Ariad Pharmaceuticals jumps on Takeda takeover news; AMAG paper suffers; Nabors deal on tap
|
11/17/2016 | SP | New Issue: JPMorgan sells $1 million 5.5% yield notes linked to AMAG Pharmaceuticals
|
8/10/2016 | SP | New Issue: JPMorgan prices $1 million 9% three-month yield notes linked to AMAG
|
12/1/2015 | SP | New Issue: Bank of Montreal prices $34.48 million Raymond James/Sabrient Systems GARP equity-tied notes
|
11/19/2015 | PP | Market Commentary: Chesapeake Energy gaps down; AMAG continues trajectory lower; Vodafone prices £600 million
|
11/19/2015 | CV | Market Commentary: Chesapeake Energy gaps down; AMAG continues trajectory lower; Vodafone prices £600 million
|
11/19/2015 | CV | Market Commentary: Morning Commentary: AMAG continues trajectory lower; Vodafone launches £500 million convertible
|
11/18/2015 | BKBWCVHY | AMAG Pharmaceuticals ends third quarter with $1.1 billion total debt
|
11/4/2015 | PP | Market Commentary: Tesla convertibles flat after earnings miss; Anthem adds on swap; FireEye contracts
|
11/4/2015 | CV | Market Commentary: Tesla convertibles flat after earnings miss; Anthem adds on swap; FireEye contracts
|
11/4/2015 | CV | Market Commentary: Morning Commentary: Convertibles primary remains quiet; Tesla Motors adds after earnings miss
|
11/3/2015 | PP | Market Commentary: AMAG Pharmaceuticals tumbles outright on earnings miss; Priceline edges up; Ctrip in line
|
11/3/2015 | CV | Market Commentary: AMAG Pharmaceuticals tumbles outright on earnings miss; Priceline edges up; Ctrip in line
|
9/25/2015 | PP | Market Commentary: Biotechnology names lower outright; AMAG Pharmaceuticals moves in line in active trade
|
9/25/2015 | CV | Market Commentary: Biotechnology names lower outright; AMAG Pharmaceuticals moves in line in active trade
|
9/25/2015 | CV | Market Commentary: Morning Commentary: AMAG Pharmaceuticals moves in line in continued active trade
|
8/20/2015 | HY | Market Commentary: Morning Commentary: High-yield lower, but new issues maintain premiums; commodities under pressure
|
8/18/2015 | HY | Market Commentary: Oneok, Hill-Rom price; new Hill-Rom notes move up; market awaits oversubscribed KIK offering
|
8/17/2015 | BK | Market Commentary: Ancestry.com finalizes spread, breaks; Osmose Holdings, JBS USA revisions surface
|
8/13/2015 | HY | Market Commentary: No pricings; Oneok hits the road; new Post, AMAG issues firm smartly; funds lose $1.21 billion
|
8/13/2015 | BKCVDDEMIGPV | Market Commentary: No pricings; Oneok hits road; new Post, AMAG issues firm smartly; funds lose $1.21 billion
|
8/13/2015 | CLHY | Market Commentary: Owens-Brockway Glass, Knowledge Universe, AMAG Pharmaceuticals, Vistage, USI free to trade
|
8/13/2015 | BK | Market Commentary: Owens-Brockway Glass, Knowledge Universe, AMAG Pharmaceuticals, Vistage, USI free to trade
|
8/13/2015 | HY | Market Commentary: Morning Commentary: Junk tracks volatile crude oil prices; Post, AMAG bonds well bid in secondary
|
8/12/2015 | HY | Market Commentary: Post two-part megadeal, upsized AMAG Pharmaceuticals price, AMAG gains; broad market lower
|
8/12/2015 | BKCVDDEMIGPV | Market Commentary: Post two-part megadeal, upsized AMAG Pharmaceuticals price, AMAG gains; broad market lower
|
8/12/2015 | CLHY | Market Commentary: Global Healthcare breaks; Getty Images declines; Multiple primary deals undergo revisions
|
8/12/2015 | BK | Market Commentary: Global Healthcare breaks; Getty Images declines; Multiple primary deals undergo revisions
|
8/12/2015 | HY | New Issue: AMAG Pharmaceuticals sells upsized $500 million 7 7/8% eight-year notes at par
|
8/12/2015 | BK | AMAG Pharmaceuticals flexes $350 million loan to Libor plus 375 bps
|
8/12/2015 | HY | Market Commentary: Morning Commentary: Amid global stock rout, junk down ½ point; Owens-Illinois paper eyed
|
8/12/2015 | HY | AMAG ups offering to $500 million, talks eight-year notes to yield 7¾%-8%; pricing Wednesday
|
8/8/2015 | HY | Market Commentary: Junk primary ends $7 billion week on a quiet note; energy credits again slide as oil drops
|
8/7/2015 | HY | Market Commentary: Morning Commentary: High yield down a quarter point, ex-energy, but recent issues holding above par
|
8/5/2015 | HY | Market Commentary: Upsized First Data drive-by leads biggest primary day since June; new Party City jumps
|
8/5/2015 | BKCVHY | Moody’s rates AMAG loan Ba2, notes B3
|
8/5/2015 | HY | AMAG Pharmaceuticals on roadshow for $450 million eight-year notes
|
8/4/2015 | CLHY | Market Commentary: PODS, Garda break; Pharmaceutical Products, Emdeon revise deals; Graton accelerates deadline
|
8/4/2015 | BK | Market Commentary: PODS, Garda break; Pharmaceutical Products, Emdeon revise deals; Graton accelerates deadline
|
8/4/2015 | BKCV | S&P lifts AMAG; rates loan BB, notes B+
|
8/4/2015 | BK | AMAG Pharmaceuticals launches $350 million loan at Libor plus 400 bps
|
7/30/2015 | CLHY | Market Commentary: Asurion, Hill-Rom, Ardent, PLZ, Mohegan break; Quality Distribution, Linxens revise deals
|
7/30/2015 | BK | Market Commentary: Asurion, Hill-Rom, Ardent, PLZ, Mohegan break; Quality Distribution, Linxens revise deals
|
7/30/2015 | BK | AMAG Pharmaceuticals to launch $350 million term loan on Tuesday
|
6/29/2015 | BKHY | AMAG plans new term loan and bonds for Cord Blood Registry purchase
|
11/12/2014 | BK | Market Commentary: AMAG, Panda Stonewall break; SeaWorld drops with earnings; WorldPay revises add-on loan
|
11/12/2014 | CLHY | Market Commentary: AMAG, Panda Stonewall break; SeaWorld drops with earnings; WorldPay revises add-on loan
|
11/6/2014 | BK | Market Commentary: Norwegian Cruise Line breaks above OID; AMAG Pharmaceuticals, Essar Steel changes surface
|
11/6/2014 | CLHY | Market Commentary: Norwegian Cruise Line breaks above OID; AMAG Pharmaceuticals, Essar changes surface
|
11/6/2014 | BK | AMAG Pharmaceuticals flexes $340 million loan to Libor plus 625 bps
|
10/31/2014 | BKCV | S&P assigns AMAG loan B+
|
10/29/2014 | BKCV | Moody’s assigns AMAG CFR B2, loan Ba3
|
10/23/2014 | BK | Market Commentary: Hargray Communications breaks; Ocwen, Walter Investment improve; DTZ flexes pricing higher
|
10/23/2014 | CLHY | Market Commentary: Hargray Communications breaks; Ocwen, Walter Investment improve; DTZ flexes higher
|
10/23/2014 | BK | AMAG Pharmaceuticals launches $340 million loan at Libor plus 550 bps
|
10/20/2014 | BK | Market Commentary: Platform Specialty, Arysta move around with acquisition news; Crown Holdings breaks atop OID
|
10/20/2014 | CLHY | Market Commentary: Platform Specialty, Arysta move around with acquisition news; Crown Holdings breaks atop OID
|
10/20/2014 | BK | AMAG Pharmaceuticals to launch $340 million term loan on Thursday
|
9/29/2014 | BK | AMAG Pharmaceuticals to get $340 million term loan for Lumara purchase
|
4/10/2014 | CV | Market Commentary: Convertibles mostly steady, some vol. names up as equities slide; WellPoint flat; AMAG slips
|
2/21/2014 | CV | Market Commentary: Midday Commentary: AMAG Pharmaceuticals trades up slightly; Brookdale responds to acquisition news
|
2/21/2014 | CV | Market Commentary: Brookdale adds dollar neutral after acquisition news; Iconix mostly in line; AMAG gains
|
2/14/2014 | CV | AMAG greenshoe lifts 2.5% five-year convertibles to $200 million
|
2/13/2014 | CV | Market Commentary: Imperial gains in modest trade; planned Akamai sees par bid; Medicines expands on hedge
|
2/12/2014 | CV | Market Commentary: Midday Commentary: Upsized AMAG, upsized Canadian Solar both add; Imperial Holdings on tap
|
2/12/2014 | CV | New Issue: AMAG Pharmaceuticals sells upsized $175 million five-year convertibles at 2.5%, up 35%
|
2/12/2014 | CV | Market Commentary: Upsized Canadian Solar jumps on debut; upsized AMAG adds; Imperial Holdings, Akamai on tap
|
2/11/2014 | CV | Market Commentary: Midday Commentary: Planned AMAG looks cheap; Canadian Solar launches $100 million deal
|
2/11/2014 | CV | Market Commentary: Planned AMAG looks cheap; Canadian Solar launches; WebMD slips outright, adds on hedge
|
2/10/2014 | CV | AMAG Pharmaceuticals plans $150 million five-year convertibles to yield 2.25%-2.75%, up 30%-35%
|
2/10/2014 | CV | Market Commentary: AMAG Pharmaceuticals offers $150 million deal; Xilinx 3.125% notes steady; Medicines down
|
1/19/2010 | CVHY | AMAG Pharmaceuticals files automatic shelf to sell debt, stock
|
7/24/2009 | SS | Market Commentary: Bristol-Meyers predicted to continue deal pace; proxy firm sides with Foundation Coal buyout
|